Inhibitors of the menin-MLL interaction

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 11919901
SERIAL NO

17744249

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction,

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • SYNDAX PHARMACEUTICALS, INC.; VITAE PHARMACEUTICALS, LLC

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cacatian, Salvacion Norristown, US 48 476
Camp, Nicholas Paul Devon, GB 18 124
Kulkarni, Santosh S Bangalore, IN 44 433
McGeehan, Gerard M Newtown Square, US 7 121
Miller, William H Collegeville, US 104 1440
Reddy, Virsinha Venkat Bangalore, IN 1 0
Samanta, Swapan Kumar Bangalore, IN 9 33

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 5, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 5, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 5, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00